US FDA grants accelerated approval to Etcamah for ESR1-mutant breast cancer
US FDA granted accelerated approval to Etcamah for advanced breast cancer with an ESR1 mutation.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.